Funds › Venrock Adviser, LLC
Venrock Adviser, LLC
13F for Q2 2026, filed Aug 14, 2026. 33 positions worth $3.3B.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Venrock Adviser, LLC in the latest 13F quarter?
Using 13F.ai, how has Venrock Adviser, LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Venrock Adviser, LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | Apogee Therapeutics Inc | 8.49M | $1.1B | 34.2% | Unchanged | 13F ↗ |
| 2 | ORKA Oruka Therapeutics, Inc. | 4.15M | $394.8M | 12.0% | Unchanged | 13F ↗ |
| 3 | ERAS Erasca, Inc. | 17.89M | $327.8M | 9.9% | +9.2% | 13F ↗ |
| 4 | SYRE Spyre Therapeutics, Inc. | 2.99M | $265.0M | 8.0% | -19.0% | 13F ↗ |
| 5 | DNTH Dianthus Therapeutics, Inc. | 1.18M | $115.0M | 3.5% | Unchanged | 13F ↗ |
| 6 | OCUL Ocular Therapeutix, Inc. | 10.35M | $101.6M | 3.1% | Unchanged | 13F ↗ |
| 7 | Damora Therapeutics Inc | 3.60M | $93.7M | 2.8% | Unchanged | 13F ↗ |
| 8 | SVRA Savara, Inc. | 14.75M | $90.8M | 2.8% | +7.3% | 13F ↗ |
| 9 | JBIO Jade Biosciences, Inc. | 3.22M | $71.6M | 2.2% | Unchanged | 13F ↗ |
| 10 | COGT Cogent Biosciences, Inc. | 1.64M | $63.6M | 1.9% | -17.9% | 13F ↗ |
| 11 | VRDN Viridian Therapeutics, Inc. | 3.26M | $59.8M | 1.8% | -16.1% | 13F ↗ |
| 12 | VOR Vor Biopharma Inc. | 3.04M | $56.0M | 1.7% | Unchanged | 13F ↗ |
| 13 | DYN Dyne Therapeutics, Inc. | 2.17M | $48.3M | 1.5% | Unchanged | 13F ↗ |
| 14 | MAZE Maze Therapeutics, Inc. | 1.60M | $47.8M | 1.4% | Unchanged | 13F ↗ |
| 15 | RLMD Relmada Therapeutics, Inc. | 6.84M | $47.4M | 1.4% | +41.3% | 13F ↗ |
| 16 | ORIC Oric Pharmaceuticals, Inc. | 4.32M | $46.8M | 1.4% | Unchanged | 13F ↗ |
| 17 | CBIO Crescent Biopharma, Inc. | 2.13M | $38.4M | 1.2% | Unchanged | 13F ↗ |
| 18 | ZURA Zura Bio Limited | 6.43M | $38.0M | 1.2% | Unchanged | 13F ↗ |
| 19 | ANL Adlai Nortye Group Ltd. · ADR | 3.21M | $36.9M | 1.1% | Unchanged | 13F ↗ |
| 20 | ELVN Enliven Therapeutics, Inc. | 526,331 | $26.7M | 0.8% | -69.5% | 13F ↗ |
| 21 | Cybin Inc | 3.85M | $25.5M | 0.8% | Unchanged | 13F ↗ |
| 22 | CGEM Cullinan Therapeutics, Inc. | 1.38M | $25.1M | 0.8% | Unchanged | 13F ↗ |
| 23 | IPSC Century Therapeutics, Inc. | 8.70M | $21.3M | 0.6% | Unchanged | 13F ↗ |
| 24 | ARTV Artiva Biotherapeutics, Inc. | 2.04M | $19.8M | 0.6% | +27.0% | 13F ↗ |
| 25 | CTMX CytomX Therapeutics, Inc. | 4.98M | $18.7M | 0.6% | -50.1% | 13F ↗ |
| 26 | ACHV Achieve Life Sciences, Inc. | 2.75M | $18.0M | 0.5% | New | 13F ↗ |
| 27 | PBLS Parabilis Medicines, Inc. | 625,000 | $17.1M | 0.5% | New | 13F ↗ |
| 28 | SRZN Surrozen, Inc. | 632,931 | $16.4M | 0.5% | Unchanged | 13F ↗ |
| 29 | KRRO Korro Bio, Inc. | 1.01M | $13.3M | 0.4% | Unchanged | 13F ↗ |
| 30 | ANRO Alto Neuroscience, Inc. | 500,000 | $13.2M | 0.4% | Unchanged | 13F ↗ |
| 31 | XFOR X4 Pharmaceuticals, Inc. | 1.93M | $9.0M | 0.3% | +485% | 13F ↗ |
| 32 | RACC Research Alliance Corporation III | 300,000 | $3.2M | 0.1% | New | 13F ↗ |
| 33 | INM InMed Pharmaceuticals Inc. | 32,685 | $50.7K | <0.1% | New | 13F ↗ |
Changes since Q1 2026
4 new, 5 added to, 5 trimmed, 4 exited, 19 unchanged. By estimated dollars.
New positions (4)
Added to (5)
Trimmed (5)
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer